|
CMPX | Compass Therapeutics, Inc. |
|
|
CMPX | Compass Therapeutics, Inc. |
| Biological Products (no Diagnostic Substances) |
| Book value per $ invested | $ 0.72 |
| Leverage | 7.21% |
| Market Cap | $ 191.2m |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -47.5m |
| Margin | -558.82% |
Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapies to treat multiple human diseases. The company is headquartered in Boston, Massachusetts.